Compare JMIA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JMIA | INBX |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.0M | 999.7M |
| IPO Year | 2018 | 2024 |
| Metric | JMIA | INBX |
|---|---|---|
| Price | $8.01 | $110.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $16.75 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 3.0M | 509.2K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $22.18 | N/A |
| Revenue Next Year | $23.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $2.89 | $12.80 |
| 52 Week High | $14.72 | $155.29 |
| Indicator | JMIA | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 48.58 |
| Support Level | $7.76 | $69.30 |
| Resistance Level | $8.43 | $155.29 |
| Average True Range (ATR) | 0.49 | 13.09 |
| MACD | 0.11 | -2.08 |
| Stochastic Oscillator | 45.00 | 14.74 |
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace that connects sellers with consumers. The logistics services of the company enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. The company generates revenue from first-party sales, third-party sales, marketing and advertising, and the provision of other services. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.